Menovazin

INSTRUCTION FOR MEDICAL USE OF THE MEDICINAL PRODUCT MENOVAZIN MENOVASINUM

Composition:

Active substances: racemic menthol, procaine hydrochloride, benzocaine;

100 ml of solution contains racemic menthol – 2.5 g, procaine hydrochloride – 1 g, benzocaine – 1 g;

Excipient: 70% ethanol.

Pharmaceutical form. Topical solution.

Main physicochemical properties: colorless, transparent liquid with a menthol odor.

Pharmacotherapeutic group.

Agents used locally for joint and muscle pain.

ATC code M02AX.

Pharmacological properties.

Pharmacodynamics.

The drug has anti-pruritic and local anesthetic effects. When applied to the skin and mucous membranes, it stimulates nerve endings, causing sensations of cold, mild burning, and tingling.

Exerts a mild analgesic effect.

Pharmacokinetics.

When used locally, the drug does not enter the bloodstream.

Clinical characteristics.

Indications.

The drug is indicated for neuralgias, myalgias, and arthralgias.

Contraindications.

The drug is contraindicated in case of hypersensitivity to procaine and other components of the drug.

Special precautions.

Do not apply to damaged skin or skin with signs of allergy. Do not apply to facial skin.

Do not violate the application instructions of the medicinal product, as this may harm health.

Interaction with other medicinal products and other types of interactions.

Components of the drug (procaine, anestezin) weaken the antibacterial effect of sulfanilamide drugs. Enhance the effects of drugs with local anesthetic action.

When using any other medicinal products simultaneously, inform your doctor.

Special precautions for use.

Use during pregnancy or breastfeeding.

The use of the drug during pregnancy and breastfeeding is possible only when the expected benefit for the mother outweighs the potential risk to the fetus or infant.

Ability to influence reaction rate when driving or operating machinery.

Has no effect.

Method of administration and dosage.

The drug is intended for topical use. Painful areas of the skin should be rubbed with Menovazin 2–3 times a day. The duration of treatment depends on the form and severity of the disease, the drug's effect, and the type of therapy (monotherapy or combined with other medicinal agents).

Children.

Do not use in children under 12 years of age.

Overdose.

With prolonged use, dizziness, general weakness, decreased arterial blood pressure, and allergic reactions may occur. If such symptoms occur, discontinue the drug, wash any residue from the skin surface with water, and administer symptomatic therapy.

Side effects.

Allergic reactions are possible (hyperemia, skin irritation, itching sensation, rash, swelling, urticaria).

If any adverse events occur, consult a physician immediately!

Shelf life. 3 years.

The product must not be used after the expiry date stated on the packaging.

Storage conditions.

Store at a temperature not exceeding 25 °C, in a place inaccessible to children.

Packaging. 40 mL or 100 mL in glass bottles; 100 mL in polymer bottles.

Supply category. Over-the-counter.

Manufacturer.

LLC "DKP "Pharmaceutical Factory".

Manufacturer's name and address of manufacturing site.

4, Korolova St., v. Stanishivka, Zhytomyr district, Zhytomyr region, 12430, Ukraine.